Alto Neuroscience, Inc. (ANRO)
(Delayed Data from NYSE)
$10.85 USD
-0.15 (-1.36%)
Updated Oct 21, 2025 04:00 PM ET
After-Market: $10.85 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANRO 10.85 -0.15(-1.36%)
Will ANRO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ANRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANRO
All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy
ANRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ANRO
Analysts’ Top Healthcare Picks: Alto Neuroscience, Inc. (ANRO), Glaukos (GKOS)
Expansion Breakout appears for ANRO after 80.92% move
Alto Neuroscience price target raised to $16 from $10 at Baird
Alto Neuroscience price target raised by $6 at Baird, here's why
Midday Fly By: AWS hit by outage, Kering sells beauty unit